A Study to Evaluate the Performance of an Advanced Algorithm with CGM in Adults, Adolescents, and Pediatrics


About this study

The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Individual is 2 - 80 years of age at time of enrollment.
  • A clinical diagnosis of type 1 or 2 diabetes for a minimum of 6 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
  • Adequate venous access as assessed by investigator or appropriate staff.
  • Subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity ratio. Subjects without ratios may participate under observation only.

Exclusion Criteria: 

  • Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by a qualified individual. 
  • Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection).
  • Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks.
  • Subject is female and has a positive pregnancy screening test.
  • Female of child bearing age and who is sexually active should be excluded if she is not using a form of contraception deemed reliable by investigator.
  • Subject is female and plans to become pregnant during the course of the study.
  • Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment.
  • Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment.
  • Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to enrollment. 
  • Subject has a history of a seizure disorder.
  • Subject has central nervous system or cardiac disorder resulting in syncope.
  • Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease.
  • Subject has a hematocrit (Hct) lower than the normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents).
  • Subject has a history of adrenal insufficiency.
  • Subject is a member of the research staff involved with the study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yogish Kudva, M.B.B.S.

Open for enrollment

Contact information:

Corey Reid B.S.



More information


Publications are currently not available

Mayo Clinic Footer